Indian Pharma Q2 FY27: checking five companies against our August thesis
Five of the eight companies in our August pharma report have now filed Q2 FY27 results. Laurus reported a second quarter above 30% EBITDA margin, the test the report set for it. Torrent's India business grew faster than in Q1, but earnings per share fell 19.5% as the JB acquisition reached the P&L. Sun's Organon costs are arriving as the report expected, Cipla's margin came back inside its guided band, and the semaglutide question Dr. Reddy's hinges on stays open until November. The summary is open to everyone.
What the August report said
The report followed eight companies and put three of them through its screen: Laurus Labs and Divi's as the capability bet, and Torrent as the India prescription-brand bet. The other five were left out for reasons that had nothing to do with business quality. For Cipla, the second engine wasn't visible yet. Dr. Reddy's was a recovery case that hinged on semaglutide supply. Lupin had guided to a slower year, Sun's FY27 carries Organon deal costs before the revenue arrives, and too much of Zydus's payoff sits beyond FY29.
The screen asked three questions. Is the shift already visible in the numbers? Has management committed to a number or a date? Can the next two to four quarters test it?
The short version
Torrent: the India business is doing what the August report expected, and slightly better. Base India revenue grew 20% against a market growing 12%. The JB "soft patch" management warned about in Q1 arrived as described, with JB revenue flat for the year. The new point is per-share earnings. Operating EBITDA rose 54%, but profit after tax fell 9.6% and diluted EPS fell 19.5%, because the JB deal brought interest, amortisation and new shares with it. The two numbers the August report watches for Torrent, India growth excluding semaglutide and base-business margin, were not disclosed this quarter.
Dr. Reddy's: a clear recovery from Q1. Gross margin came back to 52.1% from 46.5%, EBITDA margin to 20.6% from 12.5%, and India grew 17% again. But the event the August report hinged on hasn't happened yet: semaglutide supply restarts in November, subject to one last validation step. A second dated test has also come into view, the US FDA decision on the abatacept biosimilar, due 22 December.
Cipla: EBITDA margin came back to 18.7%, inside the 18.5–20% FY27 band, after 16.7% in Q1. The half year is still below the band at 17.8%, and management kept the guidance. One-India grew 12%. The US business was $172 million, $10 million more than in Q1, but well short of the roughly $250 million a quarter its year-end target implies. The second engine the August report looked for is still described in future tense: US respiratory launches waiting on approvals and supply, and biosimilars that reach the market from 2029.
Laurus: the August dashboard said two quarters at 30% EBITDA margin or more would support a structural shift. Q2 was the second: 34.5%, after 31.8% in Q1. Revenue grew 33% and profit 126%, with small-molecule CDMO up 86%. Management kept its ">30%" guidance rather than raising it, and still won't say how much of CDMO is commercial supply. Operating cash flow fell 26% and didn't cover H1 capex.
Sun: the August report left Sun out because FY27 would carry Organon costs before Organon revenue. Q2 shows exactly that: ₹346 crore of deal costs, plus a ₹923 crore US antitrust settlement, took reported profit down 36%, while adjusted profit rose 1.4%. India grew 17.3%. Innovative medicines slowed to 6.9% growth from about 13% in Q1, and US sales fell 8.2% on lenalidomide. The FY27 guidance check waits for the earnings call.